Clinical ophthalmology (Auckland, N.Z.)最新文献

{"title":"Correlation of Blood Glucose Control With Cystoid Macular Edema and Central Macular Thickness After Cataract Surgery in Diabetics.","authors":"Rui Ding, BaoHua Wu, Yan Sun, XiaoYan Zhang, HaiZhou Mi, YueRong Kong, YanGang Ma","doi":"10.2147/OPTH.S506122","DOIUrl":"10.2147/OPTH.S506122","url":null,"abstract":"<p><strong>Objective: </strong>Macular edema and retinal thickening after cataract surgery can lead to poor vision in patients, especially in the presence of high glucose. Blood glycosylated hemoglobin (HbA1c) concentration plays an important role in assessing diabetic control and is closely related to cataract surgery prognosis. The aim of this study was to investigate the correlation between postoperative HbA1c levels and postoperative cystoid macular edema (CME) and central macular thickness (CMT) in diabetic cataract patients.</p><p><strong>Methods: </strong>Retrospective analysis was conducted on 80 patients with diabetic cataracts from December 2018 to December 2023. The enrolled cases were divided into 2 groups according to the blood glucose control: 56 cases (56 eyes) in the intensive treatment group (HbA1c ≤ 7.0%) with insulin combined with oral hypoglycemic agents; and 24 cases (24 eyes) in the standard treatment group (HbA1c > 7.0%). The Student's <i>t</i>-test or paired <i>t</i>-test was used to compare the changes in CMT between the two groups at each preoperative and postoperative time period. The chi-square test was used to compare the incidence of CME at each postoperative time period. Pearson or Spearman correlation was used to analyse the relationship between HbA1c levels and CMT or CME at each postoperative time period. Predictive efficacy was analyzed using ROC curves.</p><p><strong>Results: </strong>Patients who went through the standard treatment showed significant CMT thickening and CME at 3 and 6 months postoperatively. HbA1c levels were positively correlated with CME and CMT at 1, 3, and 6 months postoperatively, with good predictive efficacy.</p><p><strong>Conclusion: </strong>Postoperative HbA1c levels have a strong correlation with CME and CMT thickening and may be reliable and valid biomarkers.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1129-1138"},"PeriodicalIF":0.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Efficacy and Safety of Preservative Free Cyclosporine in Dry Eye Disease.","authors":"Aafreen Bari, Aishwarya Dasgupta, Tushar Agarwal, Tanuj Dada, Namrata Sharma","doi":"10.2147/OPTH.S505641","DOIUrl":"10.2147/OPTH.S505641","url":null,"abstract":"<p><p>Dry eye disease (DED) is an ocular surface ailment with a high prevalence in the current era. One of the management principles involves the treatment of the underlying ocular surface inflammation. Topical Cyclosporine therapy is an effective treatment option. However, achieving an adequate drug concentration at the site of action and minimising the associated adverse drug effects, such as stinging and burning sensations at the site of instillation, are the biggest challenges. A preservative-free formulation of Cyclosporine 0.05% (Cyclisis-PF, Intas Pharmaceuticals, India) was studied in 50 patients with mild to moderate DED in a prospective interventional study. Eye drops were prescribed twice daily in addition to conventional treatment. At 12 weeks follow-up, the tear film stability was better in terms of improved tear break up time (TBUT) (p < 0.01), non-invasive break up time (NIBUT) (p < 0.001), Schirmer's test (p < 0.01), lipid layer thickness (LLT) (p = 0.006), tear meniscus height (TMH) (p < 0.01), corneal staining score (p < 0.01), and ocular surface disease index (OSDI) score (p < 0.01) at the three-month follow-up. Only five of the 50 (10%) patients had mild adverse drug effects in the form of mild stinging. However, none of the patients discontinued this drug. In conclusion, preservative free cyclosporine is a safe, effective and well tolerated treatment modality in cases of mild to moderate DED.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1149-1154"},"PeriodicalIF":0.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optometrists' Assessment of Pseudoexfoliation and Its Impact on Glaucoma Referrals.","authors":"Karin Landgren, Dorothea Peters","doi":"10.2147/OPTH.S505365","DOIUrl":"10.2147/OPTH.S505365","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the frequency and accuracy of pseudoexfoliation syndrome (PEX) assessment in referrals from primary care optometrists before the new Swedish glaucoma guidelines were established, and to evaluate an optometrist's ability to assess PEX.</p><p><strong>Patients and methods: </strong>We studied PEX assessments in 95 referrals (95 patients,189 eyes) with elevated intraocular pressure (IOP) from optometrists to the Skåne University Hospital in Malmö, Sweden, in 2019. We reviewed the frequency and accuracy of PEX assessments in referrals and compliance of these referrals with the new guidelines. In addition, an optometrist's ability to identify PEX was evaluated and compared to that of an ophthalmologist specialized in glaucoma. Patients referred were examined at the hospital for PEX, first by the study's optometrist and then by the ophthalmologist.</p><p><strong>Results: </strong>PEX was present in 17% of the patients (16 patients, 19 eyes). The optometrist in this study positively assessed PEX in 12 of 19 eyes (63%) before dilatation and in 14 of 19 eyes (74%) after dilatation. Seven referrals included a PEX assessment (3 assessed PEX and 4 assessed non-PEX), all of which were confirmed as correct. Of the 16 patients with PEX, 13 did not undergo a PEX assessment before referral. According to the new Swedish guidelines, three of the 13 referrals would not have been accepted, meaning that two patients requiring treatment would have been missed, one with pseudoexfoliation glaucoma and one with ocular hypertension with PEX.</p><p><strong>Conclusion: </strong>Very few referrals from primary care optometrists included a PEX assessment (7%). According to the new guidelines, necessary referrals would therefore have been rejected. Still, the study's optometrist detected PEX in the majority of patients. The risk of missing high risk patients requiring glaucoma treatment would be reduced if primary care optometrists assess PEX before referral.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1111-1118"},"PeriodicalIF":0.0,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationships of the Duration from Onset and Macular Morphology with Metamorphopsia After Surgery for Macula-Off Rhegmatogenous Retinal Detachment.","authors":"Tadanobu Sato, Tadamichi Akagi, Daigo Kobayashi, Akiko Anraku, Yohei Nozaki, Takumi Ando, Hiromitsu Yoshida, Hiroko Terashima, Hiruma Hasebe, Takeo Fukuchi","doi":"10.2147/OPTH.S512396","DOIUrl":"10.2147/OPTH.S512396","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the relationships among postoperative metamorphopsia and postoperative macular morphological changes and the duration from the onset of visual field disturbance to surgery (DVD) in patients who underwent surgery for macula-off rhegmatogenous retinal detachment (RRD).</p><p><strong>Patients and methods: </strong>We retrospectively reviewed 33 eyes of 33 patients who underwent pars plana vitrectomy (PPV) for macula-off RRD with known onset of symptoms of visual field disturbance at Niigata University Medical and Dental Hospital or Saiseikai Niigata Hospital and were followed up for at least 6 months postoperatively. Optical coherence tomography images of the macula obtained at 6 months postoperatively and DVD were analyzed, and the associations of the DVD with vertical metamorphopsia (vM) and horizontal metamorphopsia (hM) at 6 months postoperatively were evaluated using M-CHARTS.</p><p><strong>Results: </strong>vM was significantly correlated with the DVD and ellipsoid zone (EZ) disruption (<i>P</i> = 0.004 and <i>P</i> = 0.008, respectively), while hM was significantly correlated only with the DVD (<i>P</i> = 0.018). vM was significantly smaller in eyes with a DVD ≤ 7 days (0.34 ± 0.35)) than in eyes with a DVD ≥ 8 days (0.69 ± 0.32) (<i>P</i> = 0.005). In the multivariate analyses, postoperative vM was significantly associated with EZ disruption and the DVD (≤ 7 or ≥ 8 days) (<i>P</i> = 0.012 and <i>P</i> = 0.014, respectively).</p><p><strong>Conclusion: </strong>Metamorphopsia after PPV for macula off RRD was associated with the DVD and EZ disruption.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1119-1128"},"PeriodicalIF":0.0,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study.","authors":"Debdulal Chakraborty, Tushar Kanti Sinha, Sourav Sinha, Rupak Kanti Biswas, Aniruddha Maiti, Subhendu Boral, Arnab Das, Soumava Mandal, Ranabir Bhattacharya, Shouvick Dan, Dinesh Rungta","doi":"10.2147/OPTH.S515479","DOIUrl":"10.2147/OPTH.S515479","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the safety profiles of biosimilar ranibizumab (Razumab™) and innovator ranibizumab (Accentrix™) in the management of chorioretinal vascular diseases across a large, diverse patient cohort in a multicenter retrospective study.</p><p><strong>Methods: </strong>This multicenter, retrospective study analyzed data from 39,226 eyes treated with either biosimilar or innovator ranibizumab across 21 centers in India between January 2016 and March 2024. Eligible patients received intravitreal injections for conditions including age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic choroidal neovascularization (CNVM). Patients were followed for a minimum of three months, with adverse events documented during follow-up visits. Safety outcomes were assessed based on ocular and systemic adverse events, with statistical analyses comparing frequencies between groups using chi-square and t-tests.</p><p><strong>Results: </strong>A total of 46,520 injections were administered in the innovator group (20,283 eyes; mean 2.29±1.53 injections per eye) and 45,310 injections in the biosimilar group (18,943 eyes; mean 2.39±1.61 injections per eye). Both groups showed comparable safety profiles. Ocular adverse events were mostly mild, with similar rates of transient blurring, subconjunctival hemorrhage, and ocular pain. Serious ocular events, including endophthalmitis, were rare (2 cases in each group). Systemic adverse events, such as myocardial infarction and cerebrovascular accidents, were also rare, with no statistically significant differences between groups. A higher incidence of anterior chamber inflammation was noted in the biosimilar group (p=0.005), while headache was significantly more common in this group (p=0.0002).</p><p><strong>Conclusion: </strong>This large-scale real-world study demonstrates that biosimilar ranibizumab offers a comparable safety profile to innovator ranibizumab in the management of chorioretinal vascular diseases. The affordability of biosimilar ranibizumab enhances its potential as a cost-effective alternative, particularly in resource-limited settings, without compromising safety.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1093-1102"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Self-Test Refraction, Autorefraction, and Subjective Refraction.","authors":"Abraão Ferreira de Sousa Neto Kós, Bernardo Kaplan Moscovici, Cesar Vilar, Mario Augusto Pereira Dias Chaves, Maíra Gomes Barbosa Da Silva, Maurício Agne Neuwald, André Lins De Medeiros, Jonathan Clive Lake, Antonio Francisco Pimenta Motta, Patrick Frensel de Moraes Tzelikis, Pedro Carlos Carricondo, Larissa Gouvea, Walton Nosé, Wilson Takashi Hida","doi":"10.2147/OPTH.S510850","DOIUrl":"10.2147/OPTH.S510850","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the performance of a self-refraction device (EyeQue Vision Check 2, EyeQue, USA) with autorefraction (OPD-Scan III, NIDEK) and subjective cycloplegic refraction in measuring refractive errors.</p><p><strong>Methods: </strong>This descriptive study included 80 eyes from 40 patients. Measurements were obtained using the portable EyeQue device, OPD-Scan III, and subjective cycloplegic refraction performed by an experienced examiner. Spherical equivalent (SE), cylindrical power, and axis values were analyzed using power vector decomposition (M, J0, J45) to improve accuracy in comparing methods. The main outcome was the agreement between self-refraction, autorefraction, and subjective refraction.</p><p><strong>Results: </strong>The EyeQue device showed lower variability and greater homogeneity in spherical measurements but exhibited lower precision for cylindrical power and axis than subjective refraction. Power vector analysis revealed that EyeQue overestimated spherical equivalent (M) and produced higher J0 values, suggesting a tendency to alter cylindrical correction. Although comparable to OPD-Scan in spherical refraction, EyeQue demonstrated inconsistencies in astigmatism correction, particularly in J45 components.</p><p><strong>Conclusion: </strong>The EyeQue device is a promising tool for large-scale screenings due to its affordability and portability. However, its limitations in astigmatism and axis measurements indicate that subjective refraction should complement rather than replace it. Therefore, further refinement and validation in diverse populations are recommended.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1085-1092"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fear of Cataract Surgery and Vision Loss: The Effects of Health Literacy and Patient Comprehension at an Academic Hospital-Based Eye Clinic.","authors":"Samantha Hu, Stephanie Wey, Rainier Arthur Yano, Lisa Diane Kelly","doi":"10.2147/OPTH.S490630","DOIUrl":"10.2147/OPTH.S490630","url":null,"abstract":"<p><strong>Purpose: </strong>This qualitative study assessed the relationship between health literacy and perceptions surrounding fear of cataract surgery and fear of vision loss in patients presenting to a Midwestern, urban, safety-net hospital-based clinic setting.</p><p><strong>Patients and methods: </strong>Forty-two patients were recruited from the Hoxworth Eye Clinic at the University of Cincinnati Medical Center. The inclusion criteria were as follows: established patient at the clinic, age 50 or older, diagnosis of cataract by ICD-10 and/or physical exam, and no history of prior cataract surgery. Each patient completed a survey of demographic information and questions targeting their understanding and attitudes surrounding cataract pathology and treatment, and the Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF), a validated 7-item word recognition test assessing patient health literacy. Two-tailed t-tests assuming equal variances and chi-squared tests conducted in Excel were used in statistical analyses.</p><p><strong>Results: </strong>In our cohort (n = 42), there was no association between score on the REALM-SF and fear of cataract surgery (p = 0.87), but there was a significant association between fear of cataract surgery and belief that cataract surgery would improve vision (p = 0.03). Conversely, there was no significant association between fear of vision loss and belief that cataract surgery would improve vision (p = 0.92). The factors underlying these findings may be further clarified when attitudes surrounding cataract surgery and vision are categorized based upon best corrected visual acuity (BCVA). Patients with BCVA worse than 20/40 in only one eye fear cataract surgery more than patients with BCVA more than 20/40.</p><p><strong>Conclusion: </strong>In our patient population, neither health literacy nor understanding of cataract pathology was associated with fear of cataract surgery. However, given patients who feared cataract surgery were less likely to believe cataract surgery would improve vision, clarifying goals of surgery and addressing patient fears should be prioritized. Interestingly, this may be more important at earlier stages of non-visually significant cataracts for patients with good vision.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1103-1110"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Varenicline Solution Nasal Spray for the Treatment of Dry Eye Disease in Sjogren's Disease: A Pilot Study.","authors":"Angela S Gupta, Taylor J Linaburg, Emma Iacobucci, Patrick A Augello, Vivian L Qin, Gui-Shuang Ying, Vatinee Y Bunya, Mina Massaro","doi":"10.2147/OPTH.S512364","DOIUrl":"10.2147/OPTH.S512364","url":null,"abstract":"<p><strong>Purpose: </strong>We evaluated the efficacy of varenicline solution nasal spray (VNS) in treating dry eye disease (DED) associated with moderate to severe Sjogren's disease and analyzed tear film cytokine levels of patients with DED and Sjogren's disease before and after VNS use.</p><p><strong>Methods: </strong>This was a pilot study involving a single-center, single-arm investigator-initiated trial. Patients with moderate to severe Sjogren's disease were given VNS 0.03 mg twice daily for 28 days. Patients were assessed on day 0 before VNS use, day 14 and day 28. Clinical exam findings, symptomatology as measured by the eye dryness score, and tear cytokines were assessed at baseline and day 28.</p><p><strong>Results: </strong>Thirty-nine subjects were included. Between day 0 and day 28, there was a statistically significant improvement in the eye dryness score (p = 0.01), corneal staining (p < 0.001), and conjunctival staining (p = 0.04). There was a statistically significant increase in tear secretion by unanesthetized Schirmer's in subjects with a baseline Schirmer's ≤5 mm (n = 35 eyes, p = 0.02) and a non-statistically significant increase in tear secretion in subjects with a baseline Schirmer's of 6-10 mm (n = 16 eyes, p = 0.79). There was a statistically significant decrease in tear film cytokine concentration of IFNγ (p = 0.0003), IL-12p70 (p < 0.0001), IL-17a (p = 0.004), IL-1β (p = 0.007), IL-2 (p < 0.0001), IL-4 (p = 0.01), and TNF-α (p = 0.02), and no significant change in IL-6 (p = 0.56) and IL-10 (p = 0.18).</p><p><strong>Conclusion: </strong>Our findings add to existing evidence that VNS improves subjective dry eye symptoms, corneal and conjunctival staining, and tear secretion in a subset of tear-deficient patients, while providing new evidence that VNS reduces concentration of pro-inflammatory cytokines in the tear film.</p><p><strong>Clinical trial registration number: </strong>NCT05700422.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1073-1084"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic Muscle Stimulation of the Periorbital Area for Improvement of Blinking in Dry Eye Patients.","authors":"James G Chelnis, Alexandra Chelnis","doi":"10.2147/OPTH.S513989","DOIUrl":"10.2147/OPTH.S513989","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate whether Dynamic Muscle Stimulation technology (DMSt) in the peri-orbital area improves blinking quality in subjects with lower lid laxity and dry eye disease (DED) due to Meibomian Gland Dysfunction (MGD).</p><p><strong>Patients and methods: </strong>Eligible subjects had lower lid laxity and DED due to MGD. Treatment consisted of DMSt administered 4 times at 1-week intervals. Outcome measures were tested before each treatment and at the follow-up (FU) 4 weeks after the final treatment. The main hypothesis was a decrease in the proportion of subjects with lower lid laxity, defined as abnormal lower lid distraction test (LLDT) or abnormal snap-back test (SBT). Outcomes related to DED comprised the modified meibomian gland score (mMGS), tear breakup time (TBUT), and symptoms of DED (OSDI). Other outcomes included the Margin to Reflex Distance 1 and 2 (MRD1 and MRD2), estimation of blink rate, blink quality, and eyelid appearance.</p><p><strong>Results: </strong>30 subjects completed FU. LLDT decreased from 11.1 (SD 2.2) mm to 5.3 (SD 1.3) mm (P<0.0001). The proportion of subjects with normal LLDT and SBT increased from 3% to 80% and from 30% to 93%, respectively (p<0.0001). Lower lid laxity decreased from 100% at BL to 23% at FU (p<0.0001). MRD2 gradually decreased from 5.5 (SD 0.9) mm at BL to 5.0 (SD 0.4) mm at FU (P<0.001). TBUT, mMGS, and OSDI changed by +286%, -78%, and -53%, respectively (P<0.0001). The proportion of subjects with normal eyelid appearance, blink quality, blink rate and eyelid closure increased from 0 to 63% (p<0.0001), 0 to 73% (p<0.0001), 36% to 93% (p<0.0001) and 73% to 100% (p<0.01), respectively. No adverse events occurred.</p><p><strong>Conclusion: </strong>In DED patients, DMSt in the peri-orbital area decreases lower lid laxity and improves blinking quality. These, in turn, may be useful for managing signs and symptoms of DED due to MGD.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1057-1071"},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Timing for Intraocular Pressure Measurement Following Femtosecond Laser-Assisted Cataract Surgery: A Systematic Review and Meta-Analysis.","authors":"William J Herspiegel, Brian E Yu, Monali S Malvankar-Mehta, Cindy M L Hutnik","doi":"10.2147/OPTH.S509212","DOIUrl":"10.2147/OPTH.S509212","url":null,"abstract":"<p><strong>Purpose: </strong>Femtosecond laser-assisted cataract surgery (FLACS) has increasingly been adopted worldwide. Lagging behind is evidence-based consensus regarding optimal timing for intraocular pressure (IOP) measurement following FLACS. The purpose of this study was to determine if enough evidence currently exists to guide best practice.</p><p><strong>Methods: </strong>A comprehensive literature search was performed on MEDLINE and EMBASE until February 6th, 2023. Articles reporting IOP measurements following uncomplicated FLACS were screened. For change in IOP at various post-operative timepoints, standardized mean difference (SMD) was calculated as the mean difference in IOP from baseline. Risk of Bias Assessment was conducted following data extraction.</p><p><strong>Results: </strong>The meta-analysis incorporated six randomized clinical studies involving a total of 1356 eyes from 1032 participants. Post-operative day one was the only timepoint with a non-significant increase in IOP (SMD = -0.08 [95% CI: -0.41 to +0.24]) compared to the 7-days, 30-days, 60 to 90-days, and 180-days follow-up periods. All studies except one utilized an ophthalmic viscosurgical device (OVD) in their procedure; this was the only publication that reported a decrease in IOP from baseline within the 1-day follow-up period.</p><p><strong>Conclusion: </strong>The results suggest that the optimal time to measure IOP is within the first 24 hours after FLACS. However, these findings are limited by a small study sample. Future prospective clinical trials may be beneficial to determine if specific timepoints within the first 24 hours exist to optimize outcomes and patient reported experiences.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1045-1055"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}